Table 1 UHBFT patient demographics in relation to CMV serostatus

Median age at diagnosis in years (IQR)

58 (46–68)

62 (50–70)

50 (36–64)

< 0.001

Male gender

139 (54%)

85 (55%)

53 (52%)

0.657

GPA

160 (62%)

91 (58%)

69 (68%)

0.279

MPA

94 (36%)

63 (40%)

31 (30%)

CSS

5 (2%)

3 (2%)

2 (2%)

PR3 +ve

151 (58%)

90 (57%)

61 (60%)

0.693

MPO +ve

108 (42%)

67 (43%)

41 (40%)

Ethnicity:

0.304

 White British

229 (88%)

134 (85%)

95 (93%)

 Asian or Asian British-Pakistani

10 (4%)

7 (5%)

3 (3%)

 Asian or Asian British-Indian

7 (3%)

5 (3%)

2 (2%)

 Black or Black British-Caribbean

4 (2%)

4 (3%)

0

 Any other

9 (3%)

7 (4%)

2 (2%)

Induction treatment:

 Cyclophosphamide

199 (78%)

119 (77%)

80 (79%)

0.718

 Rituximab

8 (3%)

3 (2%)

5 (5%)

0.174

 Cyclophosphamide and rituximab

4 (2%)

3 (2%)

1 (1%)

0.553

 Azathioprine

18 (7%)

10 (6%)

8 (8%)

0.648

 Mycophenolate mofetil

15 (6%)

15 (10%)

0

0.001

 Methotrexate

7 (3%)

4 (3%)

3 (3%)

0.848

Organ involvement:

 Renal

179 (69%)

115 (73%)

64 (63%)

0.074

 ENT

62 (24%)

33 (21%)

29 (28%)

0.172

 Pulmonary haemorrhage

24 (9%)

17 (11%)

7 (7%)

0.282

 Lung

68 (26%)

42 (27%)

26 (25%)

0.822

 Nervous system

22 (8%)

16 (10%)

6 (6%)

0.224

 Eye

22 (8%)

13 (8%)

9 (9%)

0.878

Median creatinine at diagnosis μmol/L (IQR)

173 (92–407)

212 (100–422)

142 (87–374)

0.107

Dialysis requirement at diagnosis or during follow-up

45 (17%)

32 (20%)

13 (13%)

0.113

Median duration of follow-up in years (IQR)

8.5 (4.6–12.4)

8.3 (4.2–12.2)

8.9 (5.5–12.7)

0.136

Median CRP at diagnosis mg/L (IQR)

58 (16–139)

65 (20–152)

42 (12–112)

0.052

Median urine ACR at diagnosis mg/mmol (IQR)

36 (2–132)

47 (3–185)

23 (1–93)

0.069

Median serum albumin at diagnosis g/L (IQR)

35 (30–40)

35 (29–39)

36 (30–42)

0.085